The effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal and limbic catecholamine neurones in white and black mice antagonism by monoamine oxidase inhibitors Antagonism by monoamine oxidase inhibitors

[1]  D. J. Smith,et al.  The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. , 1980, The Journal of pharmacology and experimental therapeutics.

[2]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[3]  L. Olson,et al.  Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the Mouse , 1985, Journal of neurochemistry.

[4]  E. Sundström,et al.  Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. , 1985, European journal of pharmacology.

[5]  C. Marsden,et al.  Repeated administration of N-methyl-4-phenyl 1,2,5,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. , 1984, Biochemical pharmacology.

[6]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[7]  R. Duvoisin,et al.  Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine on neostriatal dopamine in mice , 1984, Neuropharmacology.

[8]  D. Jacobowitz,et al.  A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[9]  C. Rebert,et al.  Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.

[10]  N. Castagnoli,et al.  Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. , 1984, Biochemical and biophysical research communications.

[11]  J. Wikel,et al.  Depletion of cardiac norepinephrine in rats and mice by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1984, Biochemical pharmacology.

[12]  M. Yahr,et al.  Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. , 1984, European journal of pharmacology.

[13]  X. Breakefield,et al.  Specificity of antisera prepared against pure bovine MAO-B , 1983, Brain Research.

[14]  B. Parsons,et al.  Quantitative autoradiography of [3H]MPTP binding sites in rat brain. , 1984, European journal of pharmacology.

[15]  X. Breakefield,et al.  Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[17]  S. Markey,et al.  The Neurotoxicity of 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in the Monkey and Man , 1984, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[18]  B. Parsons,et al.  High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase. , 1984, European journal of pharmacology.

[19]  C. Marsden,et al.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset , 1984, Neuroscience Letters.

[20]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[21]  U. Bondesson,et al.  Melanin affinity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, an inducer of chronic parkinsonism in humans. , 2009, Acta pharmacologica et toxicologica.

[22]  S. Markey,et al.  Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. , 1984, European journal of pharmacology.

[23]  J. Fozard,et al.  (E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase. , 1984, Journal of medicinal chemistry.

[24]  S. Snyder,et al.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.